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To the Editor:
I appreciated the recent editorial 
of Menezes and Roberts on the harms 
of lung cancer screening.1 I also appre-
ciated their comments on our paper 
published in the same issue.2 I agree 
that we need to identify strategies to 
mitigate the negative physical and psy-
chological consequences of screening.
I would like to underline, how-
ever, that their comments focused only 
on one of the less important features 
of our diagnostic protocol: we consid-
ered false positive (FP) cases as those 
found benign after surgical biopsy, 
instead of adopting the more usual 
FP definition as nodules identified on 
screening CT but nonprogressive over 
the long term. Menezes and Roberts 
commented that this definition change 
did not decrease harms to the screened 
individuals. We agree.
They did not mention, however, 
that the main findings of our study 
were that a low number of subjects with 
benign nodules underwent surgery, and 
that the recall rate was low, both thanks 
to the adoption of a noninvasive nodule 
work-up protocol. Thus our recall rate 
of 10% was considerably lower than the 
27% of the NLST.3 Our figure of 14% 
undergoing “useless surgery” compared 
well with the 29% of the NLST, where 
no diagnostic protocol was suggested to 
participating centers.
The main message of our paper 
was that the physical harms of screen-
ing can be limited when a (noninva-
sive) diagnostic protocol is adopted, 
when PET-CT and VDT are used rou-
tinely instead of lung biopsy, when a 
5-mm instead of 4-mm threshold is 
adopted for investigating noncalcified 
nodules,2,4 and when positive cases are 
routinely discussed at multidisciplinary 
meetings.
Our change in FP definition may 
be important because the low specific-
ity characteristic of the old FP defini-
tion may adversely affect the perception 
of the public and health policy-makers 
regarding the risks and benefits of lung 
cancer screening.
Giulia Veronesi, MD
Division of Thoracic Surgery
European Institute of Oncology
Milan, Italy 
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mediastinum, bilateral pulmonary nod-
ules, and mediastinal lymphadenopathy 
(Fig. 1). Lung biopsy and positron emis-
sion tomography scan confirmed stage 
IV (T4N2M1a) squamous cell carcinoma 
of the lung. Tumor tissue samples ana-
lyzed locally using Multiplex polymerase 
chain reaction/mass spectroscopy did not 
reveal activating mutations in the panel 
of genes tested (Table 1).
Because of the contraindication 
of DNA cross-linking agents in the set-
ting of FA, the patient initially received 
reduced doses of gemcitabine and 
vinorelbine achieving a good response 
to therapy lasting approximately 1 year. 
Subsequently, he received two cycles 
of paclitaxel with rapid progression of 
the disease. At this point, his original 
tissue samples were sent to an outside 
laboratory for further mutation testing 
by Next Generation Sequencing which 
revealed EGFR (P733T) and TP53 
(A159P) gene mutations (Table 1).
He was treated with erlotinib 
achieving disease stabilization lasting for 
4 months. He then participated in a phase 
II trial of an experimental heat shock pro-
tein inhibitor (HSP90). Unfortunately, 
after a month of experimental therapy, 
his disease progressed and he withdrew 
from the trial. The patient died in 2014, 
29 months after his initial diagnosis.
DISCUSSION
To our knowledge, this is the first 
case report detailing the molecular pro-
file of lung cancer in a patient with FA 
and the clinical course of a patient with 
the EGFR P733T mutation.
It is well known that patients with 
FA living into adulthood are prone to 
develop hematologic malignancies and 
solid tumors.1 In fact, if the risks of aplastic 
anemia and leukemia are removed, 75% of 
patients with FA will develop a solid tumor 
by the age of 45 years.2 The most common 
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To the Editor:
A 32-year-old male with a 10-pack-
year smoking history and Fanconi 
anemia (FA) with somatic mosaicism 
presented to the emergency department 
in 2011 with a right-sided pneumotho-
rax. A computed tomography scan of 
the chest revealed a 4.4 × 3.8 cm mass 
in the left lung apex extending into the 
